SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026
SeaStar Medical (ICU) announced acceptance of a late-breaking abstract for presentation at ASN Kidney Week on October 22, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SeaStar Medical (ICU) announced acceptance of a late-breaking abstract for presentation at ASN Kidney Week on October 22, 2026.
The abstract evaluates post-approval SAVE Registry data, comparing the pediatric Selective Cytopheretic Device surveillance registry with a historical cohort in pediatric sepsis-associated acute kidney injury. Poster TH-PO1291 will be presented from 10:00 a.m. to 12:00 p.m. MT in Exhibit Hall A at the Colorado Convention Center in Denver. The meeting runs October 21–25, 2026.
Key Terms
aki medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENVER, Oct. 02, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that a late-breaking abstract evaluating the results of the post-approval SAVE Registry data has been accepted for a special late-breaker poster presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2026 meeting, taking place in Denver, CO, October 21 – 25, 2026.
Presentation Details:
Authors: Nathan L. Kleinman, Stuart Goldstein, Rajit K. Basu, Theresa A. Mottes, David J. Askenazi, Stephen Gorga, Shina Menon, Matt S. Zinter, Keri A. Drake, David A. Zolezzi, Robert S. Gillespie, Sai Prasad N. Iyer, Emily Scribe, Kevin K. Chung
Abstract / Poster Number: TH-PO1291
Date & Time: October 22, 2026, from 10:00 a.m. to 12:00 p.m. MT
Location: Exhibit Hall A, Colorado Convention Center
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal clinical trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
Contact:
IR@SEASTARMED.COM
QUELIMMUNE is a registered trademark of SeaStar Medical Holding Corporation.
